日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity

MET增强Amivantamab与EGFR的结合以及抗体依赖性细胞毒性

Sato, Shigeki; Yilmaz, Neval; Arai, Sachiko; Sakai, Katsuya; Sato, Hiroki; Murase, Yuya; Ueda, Tsukasa; Koba, Hayato; Nanjo, Shigeki; Tambo, Yuichi; Kotani, Hiroshi; Fukuda, Koji; Taniguchi, Hiroaki; Amyot, Romain; Flechsig, Holger; Isozaki, Hideko; Matsumoto, Kunio; Yano, Seiji

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

MUCIN 1 赋予非小细胞肺癌对酪氨酸激酶抑制剂耐药性的炎症记忆。

Takamori Shinkichi, Haratake Naoki, Bhattacharya Atrayee, Kikutake Chie, Ozawa Hiroki, Shigeta Keisuke, Nakashoji Ayako, Isozaki Hideko, Shimokawa Mototsugu, Suyama Mikita, Hashinokuchi Asato, Takada Kazuki, Toyokawa Gouji, Yamada Yuichi, Takenaka Tomoyoshi, Taguchi Kenichi, Yamaguchi Masafumi, Yoshizumi Tomoharu, Hata Aaron N, Kufe Donald

Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.

在非小细胞肺癌细胞中,MUC1-C 整合了 APOBEC3 胞苷脱氨酶和内源性逆转录病毒的激活

Haratake Naoki, Takamori Shinkichi, Isozaki Hideko, Shigeta Keisuke, Kikutake Chie, Ozawa Hiroki, Bhattacharya Atrayee, Nakashoji Ayako, Suyama Mikita, Takenaka Tomoyoshi, Yoshizumi Tomoharu, Osoegawa Atsushi, Hata Aaron N, Kufe Donald

EXTH-42. Lost in translation: Do preclinical studies predict clinical failure in GBM?

EXTH-42. 翻译中的误区:临床前研究能否预测 GBM 的临床失败?

Ochi, Nobuaki; Yamane, Hiromichi; Hotta, Katsuyuki; Fujii, Hiromi; Isozaki, Hideko; Honda, Yoshihiro; Yamagishi, Tomoko; Kubo, Toshio; Tanimoto, Mitsune; Kiura, Katsuyuki; Takigawa, Nagio; Andrade, R P L; Gil, N P; Costa, A L; Brás, J; Castro, N; Sousa, R; Vaz, R P; Martins, J; Almeida, E; Abreu, J; Afonso, H; Jungwirth, Gerhard; Paul, Adrian; Junguo, Cao; Unterberg, Andreas; Abdollahi, Amir; Herold-Mende, Christel; Selvi, P; Pérez, O Montero; Madroñal, IM Carrión; Yañez, D; Martin, CBocanegra; Karbhari, Nishika; Kizilbash, Sani; Campian, Jian; Elmquist, William; Galanis, Evanthia; Sarkaria, Jann

Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial

克唑替尼治疗既往接受过阿来替尼治疗的携带 EML4-ALK 融合基因的复发性非小细胞肺癌:一项 II 期试验

Harada, Daijiro; Isozaki, Hideko; Kozuki, Toshiyuki; Yokoyama, Toshihide; Yoshioka, Hiroshige; Bessho, Akihiro; Hosokawa, Shinobu; Takata, Ichiro; Takigawa, Nagio; Hotta, Katsuyuki; Kiura, Katsuyuki

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

EGFR突变型非小细胞肺癌中奥希替尼获得性耐药的现状及奥希替尼联合BLU-667治疗获得性RET融合的EGFR和RET联合抑制的临床验证

Piotrowska, Zofia; Isozaki, Hideko; Lennerz, Jochen K; Gainor, Justin F; Lennes, Inga T; Zhu, Viola W; Marcoux, Nicolas; Banwait, Mandeep K; Digumarthy, Subba R; Su, Wenjia; Yoda, Satoshi; Riley, Amanda K; Nangia, Varuna; Lin, Jessica J; Nagy, Rebecca J; Lanman, Richard B; Dias-Santagata, Dora; Mino-Kenudson, Mari; Iafrate, A John; Heist, Rebecca S; Shaw, Alice T; Evans, Erica K; Clifford, Corinne; Ou, Sai-Hong I; Wolf, Beni; Hata, Aaron N; Sequist, Lecia V

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

ALK抑制剂获得性耐药机制及ALK阳性肺癌治疗的理论依据

Isozaki, Hideko; Takigawa, Nagio; Kiura, Katsuyuki

Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography

利用正电子发射断层扫描检测到的弥漫性大B细胞淋巴瘤的皮肤受累情况

Yamane, Hiromichi; Ochi, Nobuaki; Isozaki, Hideko; Yamagishi, Tomoko; Honda, Yoshihiro; Takigawa, Nagio